Allarity Therapeutics financials
$0.9651−0.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $320.0K | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $320.0K | $0.00 | $0.00 | $0.00 | — |
| Gross margin | 100.0% | — | — | — | — |
| Operating income | -$12.6M | -$27.2M | -$17.1M | -$34.5M | -$26.6M |
| Net income | -$11.2M | -$25.2M | -$20.4M | -$21.1M | -$26.6M |
| Net margin | −3509.7% | — | — | — | — |
| Diluted EPS | $-0.78 | $-15.65 | $-6031.31 | $-3093.46 | $-140784000.00 |
| EBITDA | -$12.6M | -$17.5M | -$17.1M | -$16.8M | -$26.4M |
| Operating cash flow | -$14.8M | -$17.4M | -$12.7M | -$16.8M | -$14.9M |
| Free cash flow | -$14.8M | -$17.6M | -$12.7M | -$16.8M | -$14.9M |
| Diluted shares | 14.4M | 1.6M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $14.7M | $19.5M | $166.0K | $2.0M | $19.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $1.4M | $1.4M | $1.3M | $3.7M | $0.00 |
| Total assets | $18.3M | $22.6M | $11.9M | $14.5M | $49.6M |
| Total liabilities | $8.4M | $10.8M | $14.6M | $12.7M | $30.8M |
| Shareholders' equity | $9.8M | $11.8M | -$2.8M | -$113.0K | $18.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology